X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Abbott India Fact Sheet, Abbott India Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Abbott India Fact Sheet   (KNOL)

Here is the latest financial fact sheet of Abbott India. For more details, see the Abbott India quarterly results and Abbott India share price and chart. For a sector overview, read our pharmaceuticals sector report.

ABBOTT INDIA Price History

Price Rs 5,788.4
Mkt Cap Rs m 123,004
Vol '000 0.5
P/E X 44.5
P/CF X 44.9
EPS (TTM) Rs 130.2
% ch % 0.7
No. of shares m 21.25
% ch week % 4.5
% ch 1-mth % 5.1
% ch 12-mth % 28.1
52 week H/L Rs 6,110.0/3,996.0
(As on Feb 23, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

ABBOTT INDIA Financials

No. of Mths
Year Ending
12
Dec-11
12
Dec-12
15
Mar-14
12
Mar-15
12
Mar-16
5-Yr Chart
Click to enlarge
ABBOTT INDIA EQUITY SHARE DATA
High Rs1,6831,8071,7934,1196,015 
Low Rs1,1781,3751,3003,7003,707 
Sales per share (Unadj.) Rs701.3777.71,080.91,077.31,236.9 
Earnings per share (Unadj.) Rs56.768.193.4107.7122.2 
Diluted earnings per shareRs56.768.193.4107.7122.2 
Cash flow per share (Unadj.) Rs63.777.3103.7114.8129.0 
Dividends per share (Unadj.) Rs17.0017.0023.0031.0035.00 
Adj. dividends per shareRs17.0017.0023.0031.0035.00 
Dividend yield (eoy) %1.21.11.50.80.7 
Book value per share (Unadj.) Rs256.0304.4370.8441.2521.2 
Adj. book value per shareRs256.0304.4370.8441.2521.2 
Shares outstanding (eoy) m21.2521.2521.2521.2521.25 
Bonus/Rights/Conversions  A---- 
Price / Sales ratio x2.02.01.43.63.9 
Avg P/E ratio x25.323.416.636.339.8 
P/CF ratio (eoy) x22.520.614.934.137.7 
Price / Book Value ratio x5.65.24.28.99.3 
Dividend payout %30.025.024.628.828.6 
Avg Mkt Cap Rs m30,39833,80932,85883,079103,296 
No. of employees `0002.42.72.82.93.0 
Total wages/salary Rs m1,6732,0622,9973,0543,370 
Avg. sales/employee Rs Th6,145.26,196.88,304.07,985.18,891.8 
Avg. wages/employee Rs Th689.9773.21,083.71,065.21,140.0 
Avg. net profit/employee Rs Th496.4542.6717.5798.6878.3 
ABBOTT INDIA INCOME DATA
Net Sales Rs m14,90216,52722,96922,89326,284 
Other income Rs m197223482476504 
Total revenues Rs m15,09916,75023,45123,36926,789 
Gross profit Rs m1,7552,0182,6833,1233,665 
Depreciation Rs m150195219149144 
Interest Rs m00158 
Profit before tax Rs m1,8022,0462,9463,4444,017 
Minority Interest Rs m00000 
Prior Period Items Rs m-430000 
Extraordinary Inc (Exp) Rs m0104000 
Tax Rs m5557039611,1541,421 
Profit after tax Rs m1,2041,4471,9852,2902,596 
Gross profit margin %11.812.211.713.613.9 
Effective tax rate %30.834.432.633.535.4 
Net profit margin %8.18.88.610.09.9 
ABBOTT INDIA BALANCE SHEET DATA
Current assets Rs m6,8637,7399,96512,26114,446 
Current liabilities Rs m2,3852,29630,6123,9694,725 
Net working cap to sales %30.032.9-89.936.237.0 
Current ratio x2.93.40.33.13.1 
Inventory Days Days6258576151 
Debtors Days Days3231172120 
Net fixed assets Rs m8001,0929951,0001,113 
Share capital Rs m212213213213213 
"Free" reserves Rs m5,1736,2007,6109,10710,808 
Net worth Rs m5,4416,4697,8799,37511,076 
Long term debt Rs m00000 
Total assets Rs m7,9139,07111,39213,73616,241 
Interest coverage xNM10,231.03,682.9689.7497.0 
Debt to equity ratio x00000 
Sales to assets ratio x1.91.82.01.71.6 
Return on assets %15.216.017.416.716.0 
Return on equity %22.122.425.224.423.4 
Return on capital %32.333.237.436.836.3 
Exports to sales %0.40.70.60.50.6 
Imports to sales %7.910.715.99.912.6 
Exports (fob) Rs m59120141122162 
Imports (cif) Rs m1,1761,7643,6592,2643,322 
Fx inflow Rs m113179240215268 
Fx outflow Rs m1,5172,1174,0412,7373,927 
Net fx Rs m-1,404-1,937-3,801-2,523-3,659 
ABBOTT INDIA CASH FLOW
From Operations Rs m 241 1,014 1,545 2,148 2,514 
From Investments Rs m 51 -585 -1,431 -1,867 -800 
From Financial Activity Rs m -420 -420 -424 -576 -803 
Net Cashflow Rs m -129 8 -309 -295 912 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 0.0%
Foreign collaborators 75.0%
Indian inst/Mut Fund 7.9%
FIIs 0.1%
ADR/GDR 0.0%
Free float 17.1%
Shareholders 18,270
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF 3-4, Corporate Park, Sion Trombay Road, Mumbai - 400 071
E-MAIL investor.relations@abbott.co.in WEB www.abbott.co.in
TELEPHONE (022) 6797 8888 FAX (022) 6797 8727
SECTOR PHARMACEUTICALS GROUP M N C
TR AGENT Sharepro Serv., 13 AB, Samhita Warehousing, 2nd Flr, Andheri (E), Mumbai-72
AUDITOR Deloitte Haskins & Sells
CHM: Munir Shaikh COMP SEC: Krupa Anandpara YEAR OF INC: 1944 BSE CODE: 500488 FV (Rs): 10 DIV YIELD (%): 0.6

More Pharmaceuticals Company Fact Sheets:   SUN PHARMA  PLETHICO PHARMA  IPCA LABS  UNICHEM LAB  PFIZER  

Compare ABBOTT INDIA With:   SUN PHARMA  PLETHICO PHARMA  IPCA LABS  UNICHEM LAB  PFIZER  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ABBOTT INDIA

ABBOTT INDIA - ADCOCK INGRAM COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS